$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
多吉美在甲状腺癌治疗方面的贡献
2025-10-19 11:44:20
Check Details
卡博替尼治疗髓样甲状腺癌
2025-10-19 11:44:20
Check Details
达沙替尼及与卡博替尼联合用于治疗弥漫性脑桥脑胶质瘤的临床前评价
2025-10-19 11:44:20
Check Details
索拉非尼降低分化型甲状腺癌患者死亡风险
2025-10-19 11:44:20
Check Details
卡博替尼克服ROS1融合癌细胞系的克唑替尼耐药性
2025-10-19 11:44:20
Check Details
卡博替尼与吉非替尼联合应用于ROS1融合克唑替尼耐药肺癌
2025-10-19 11:44:20
Check Details
卡博替尼在分化型甲状腺癌患者中的I期研究
2025-10-19 11:44:20
Check Details
卡博替尼治疗肾细胞癌患者的I期研究
2025-10-19 11:44:20
Check Details
卡博替尼和转移性甲状腺癌:病例报告
2025-10-19 11:44:20
Check Details
卡博替尼治疗RET融合阳性肺腺癌患者
2025-10-19 11:44:20
Check Details
卡博替尼延长甲状腺髓样癌无进展生存期
2025-10-19 11:44:20
Check Details
乐伐替尼针对碘难治性分化型甲状腺癌的治疗
2025-10-19 11:44:20
Check Details
1
2
...
2445
2446
2447
2448
2449
2450
2451
...
4159
4160
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
2
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
3
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
4
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
5
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
6
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
7
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy
8
Sotorasib (Lumakras): A Comprehensive Guide to the First KRAS G12C-Targeted Inhibitor
9
Comprehensive Interpretation of Osimertinib: Efficacy, Side Effects and Medication Standards
10
Sotorasib: Can the First KRAS G12C-Targeted Therapy Cure Cancer?
11
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
12
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights